Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport

Citation for published version:
Adalbert, R, Milde, S, Durrant, C, Ando, K, Stygelbou, V, Yilmaz, Z, Gould, S, Brion, J-P & Coleman, M 2018, ‘Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport’, Neurobiology of Aging, vol. 68, pp. 68-75.

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Neurobiology of Aging

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport

Robert Adalbert, Stefan Milde, Claire Durrant, Kunie Ando, Virginie Stygelboult, Zehra Yilmaz, Stacey Gould, Jean-Pierre Brion, Michael P. Coleman

A Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, UK
b John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
c Laboratory of Histology, Neuroanatomy and Neuropathology, Faculty of Medicine, ULB Neuroscience Institute, Université Libre de Bruxelles, Brussels, Belgium

ARTICLE INFO

Article history:
Received 27 October 2017
Received in revised form 27 February 2018
Accepted 29 March 2018
Available online 5 April 2018

Keywords:
Axonal transport
Alzheimer's disease
FTDP-17T
P301L mutation
Aβ
Mitochondria

ABSTRACT

In Alzheimer's disease, many indicators point to a central role for poor axonal transport, but the potential for stimulating axonal transport to alleviate the disease remains largely untested. Previously, we reported enhanced anterograde axonal transport of mitochondria in 8- to 11-month-old MAPTP301L knockin mice, a genetic model of frontotemporal dementia with parkinsonism-17T. In this study, we further characterized the axonal transport of mitochondria in younger MAPTP301L mice crossed with the familial Alzheimer's disease model, TgCRND8, aiming to test whether boosting axonal transport in young TgCRND8 mice can alleviate axonal swelling. We successfully replicated the enhancement of anterograde axonal transport in young MAPTP301L/P301L knockin animals. Surprisingly, we found that in the presence of the amyloid precursor protein mutations, MAPTP301L/P301L impaired anterograde axonal transport. The numbers of plaque-associated axonal swellings or amyloid plaques in TgCRND8 brains were unaltered. These findings suggest that amyloid-β promotes an action of mutant tau that impairs axonal transport. As amyloid-β levels increase with age even without amyloid precursor protein mutation, we suggest that this rise could contribute to age-related decline in frontotemporal dementia.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Alzheimer's disease (AD) is the most common form of dementia and is characterized by the presence of amyloid plaques and neurofibrillary tangles in brain tissue (Masters et al., 2015). Many studies indicate that axonal transport defects play an important role in the pathogenesis of AD, and overexpression of tau, whose mutation causes some types of frontotemporal dementia, has also been reported to impair axonal transport (Bertrand et al., 2013; Ittner et al., 2008; Majid et al., 2014). Axonal transport is impaired in several amyloid and tau mouse models, and further impairment of transport increases pathology (Adalbert and Coleman, 2013; De Vos et al., 2008; Millecamps and Julien, 2013). These include transgenic mouse models overexpressing amyloid precursor protein (APP) or familial Alzheimer's disease (FAD) mutant APP (Salehi et al., 2006; Stokin et al., 2005), mutant presenilin-1 (Lazarov et al., 2007), and wild-type and frontotemporal dementia with parkinsonism (FTDP) mutant tau (Ishihara et al., 1999; Zhang et al., 2004). The mechanisms by which the pathologic forms of APP, tau, PS1, and amyloid-β (Aβ) disrupt axonal transport are not properly understood. Aβ itself and overexpression of either wild-type and FTDP tau disrupt axonal transport of a variety of cargos including mitochondria (Hiruma et al., 2003; Rui et al., 2006; Stamler et al., 2002; Zhang et al., 2004). Live-imaging studies of axonal transport in nervous system tissue have largely focused on mitochondria (Gilley et al., 2012; Mar et al., 2014; Marinkovic et al., 2012; Milde et al., 2015; Misgeld et al., 2007). We have reported live imaging of peripheral nerve explants of mitochondrial transport in a MAPTP301L/P301L knockin mutant mouse and in normal aging (Gilley et al., 2012; Milde et al., 2015).

Axonal swellings are a pathologic feature common to human AD and to mice expressing pathogenic forms of APP or tau and mice expressing ApoE4 (Lewis et al., 2000; Tousse et al., 2000; Wirths et al., 2001).
Our earlier study showed that large axonal swellings in one FAD model, TgCRND8 mice, precede axon loss by many months and that axonal transport may be disrupted specifically at these swellings (Adalbert et al., 2009). TgCRND8 mice inherit a highly aggressive amyloidopathy caused by the expression of double mutant amyloid precursor protein (APP; K670N/M671L plus V717F) (Chisti et al., 2001), leading to early dystrophic neurites and some cell death (Bellucci et al., 2007). These findings raise the question of whether boosting axonal transport can alleviate the pathology. Until now, very few methods have been available to enhance axonal transport in vivo, and no studies have addressed whether this type of intervention can alleviate amyloidopathy or the associated axonal damage. There have been encouraging results using microtubule (MT)-stabilizing agents, such as those used in the treatment of cancer, to improve axonal transport in tauopathy models (Brunden et al., 2012; Zhang et al., 2005). These drugs, however, elicit severe side effects, especially as they have to be administered on a chronic basis, including axonal damage in peripheral neuropathy (Boyette-Dalira et al., 2013). In previous work, we have enhanced axonal transport of mitochondria in young mice without adverse effects by knocking in the P301L mutation of MAPT (Giley et al., 2012), a mutation causing FTD-17T in humans (Wolfe, 2009). The effect on axonal transport was reversed as animals aged, suggesting other changes during aging alter how axons react to mutant MAPT. The mice remained healthy during the normal life span, with no overt tau pathology, motor, behavioral, or memory deficits. The initial aim of this study, therefore, was to test whether boosting axonal transport in young TgCRND8 mice by crossing them to MAPT<sup>P301L</sup> knockin mice could alleviate axonal swelling.

We found no alterations in the number of plaque-associated axonal swellings or the number of amyloid plaques in TgCRND8 brains when MAPT mutation was introduced. However, while we successfully confirmed the enhancement of axonal transport in young MAPT<sup>P301L/P301L</sup> mice and observed a trend in MAPT<sup>P301L/+</sup> mice more representative of FTD-17T patient genetics, the mitochondrial transport in the peripheral nerve axons of TgCRND8 mice showed a significant decrease in the presence of MAPT<sup>P301L/P301L</sup>, similar to that found in older MAPT<sup>P301L/P301L</sup> mice. This suggests increasing amyloid beta peptide, or other APP processing products reverses an action of mutant tau on axonal transport and may contribute to a similar switch observed during normal aging.

### 2. Material and methods

#### 2.1. Animals

All animal work was approved by the Babraham Institute Animal Welfare and Ethical Review Body and UK Home Office and carried out in accordance with the Animals (Scientific Procedures) Act, 1986, under Project Licenses 80/2254 and 70/7620.

First to confirm whether the enhanced mitochondrial transport is found in 3-month-old homozygous MAPT<sup>P301L</sup> knockin mice (MAPT<sup>P301L/P301L</sup>), knockin mice were crossed with Mito-P (Thy1-1-mitoCFP-P) mice as previously described (Giley et al., 2012; Misgeld et al., 2007). Mito-P mice were kindly provided by Prof. Martin Kerschensteiner (University Munich) and Prof. Thomas Misgeld (TU Munich). Heterozygous male TgCRND8 mice (Chistli et al., 2001) on a 50:50 C57BL/6;129Sv background were bred to double homozygous MAPT<sup>P301L</sup> knockin/Mito-P or MAPT<sup>P301L</sup> knockin/YFP-H (Thy1.2-YFP-H) (Feng et al., 2000) female mice to generate triple heterozygotes TgCRND8/MAPT<sup>P301L</sup>/Mito-P or TgCRND8/MAPT<sup>P301L</sup>/YFP-H mice. These triple heterozygotes were backcrossed to MAPT<sup>P301L</sup> homozygotes to generate offspring that were heterozygous for mutant APP and Mito-P (or YFP-H) and homozygous for MAPT<sup>P301L</sup>. Those mice which were heterozygous for Mito-P were used for transport studies, whereas those with YFP-H were used to assess histopathology. Controls without MAPT<sup>P301L</sup> knockin were generated by crossing to non-MAPT<sup>P301L</sup> mice on the same genetic background. Animals were kept on a 12:12 hours light/dark cycle at a constant temperature of 19 °C in a pathogen-free environment with up to 5 animals per cage.

#### 2.2. Live imaging of axonal transport and image analysis

Imaging of mitochondrial transport and analysis was performed as described previously (Giley et al., 2012; Milde et al., 2015). Briefly, mitochondrial movements were imaged in sciatic nerve explants using an Olympus Cell<sup>B</sup> imaging system (IX81 microscope, Hamamatsu ORCA ER camera, ×100 1.45 NA apochromat objective). Peripheral nerves were used as a surrogate for central nervous system (CNS) tissue because in our hands quantitative analysis of axonal transport here is more reproducible than in CNS (Milde et al., 2015), but the presence of Aβ in peripheral nerves was confirmed (Fig. 2). During imaging, tissues were maintained in oxygenated Neurobasal-A medium at 37 °C in an environment chamber (Solent Scientific Ltd). Images were captured using fixed light intensity and camera exposure time settings at a rate of 2 frames per second for 5 minutes. Five to 10 individual movies (often containing multiple axons) were captured for each tissue explant. Individual axons were straightened using the Straighten plugin in ImageJ software, version 1.44 (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, MD, USA; http://imagej.nih.gov/ij/, 1997e2012). Axonal transport parameters were determined for individual axons using the Difference Tracker set of ImageJ plugins (Andrews et al., 2010). The principal output of these plugins is the number of moving particles identified in each frame of the image, normalized to axon length (presented as particle count per second per 100 μm axon length).

#### 2.3. Histology and staining

Mice were perfused transcardially with 4% phosphate-buffered paraformaldehyde, and brains and spinal cords processed as previously described (Adalbert et al., 2009). Sagittal brain sections were cut at 50 μm, and serial transverse spinal cord sections were cut at 25 μm through the L3–L5 segments using a Leica CM 1850 cryostat. To stain fibrillar amyloid deposits, brain sections were incubated in 0.02% Thioflavine S in tris-buffered saline (TBS) for 10 minutes and then rinsed in 50% ethanol in TBS and 100% TBS before mounting in Vectashield Mounting Medium. For motor neuron analysis, the spinal cord sections were stained with 0.5% cresyl violet (Adalbert et al., 2006). The excised YFP-H sciatic nerves were incubated in 1% Triton X-100 (Sigma) in 0.1M PBS for 10 minutes at room temperature, washed extensively in 0.1M PBS, and then mounted in Vectashield.

#### 2.4. Microscopy and quantitative/qualitative analysis

The stained sections were imaged with an Olympus FV1000 confocal microscope imaging system using a 40× NA 1.3 or 63 × NA 1.4 oil immersion objective. Neuronal structures and amyloid plaques were scanned using a multitrack configuration with laser excitation (ex.) lines and emission (em.) filters as follows: Thioflavine S 405 nm ex. 475–525 nm em. and YFP 488 nm ex. 505–550 nm em. Single confocal slices or z-stacks at 0.4–0.5 mm steps were acquired to generate the data images. Conventional fluorescence imaging was carried out using an Olympus IX 81 inverted microscope coupled to an Olympus U-TV0.5Xc digital camera system. Bright-field images of Nissl-stained sections were acquired using an Olympus BX41 upright microscope (40× objective) and MicroPublisher 3.3 camera (Qimaging).
The number of amyloid plaques stained with Thioflavin S was determined in 6 sagittal sections (3 sections/hemisphere) as previously described (Adalbert et al., 2009). Amyloid plaques that had at least 1 YFP-containing axonal dystrophy (cutoff size of the dystrophy 5 μm) in the immediate vicinity were counted as plaques associated with axonal swellings. Cresyl violet-stained motor neurons with centrally placed nuclei and cytoplasm rich in rough endoplasmic reticulum were considered normal morphology. Every second section from L3–L5 spinal cord segments was qualitatively analyzed. YFP positive axons from sciatic and tibial nerves with no fragmentation or swellings along their length were classified as intact (Beirowski et al., 2004).

2.5. Aβ ELISA

To determine the levels of human Aβ1–42 in brain and sciatic nerve, samples were analyzed using a commercially available ELISA kit (Life Tech: KHB3441). Brain and sciatic nerves were
homogenized in 5 M guanidine hydrochloride (8 mL per gram of tissue) supplemented with 1x Protease Inhibitor Cocktail (Roche) for 3–4 hours at room temperature. The sample was then frozen at −20 °C until use. Before running in the ELISA, the homogenate was diluted 1:50 in ice cold reaction buffer (Dulbecco’s PBS +0.03 % Tween +5 % BSA supplemented with 1x Protease Inhibitor Cocktail) and centrifuged for 20 minutes at 4 °C at 16,000 × g. The supernatant was then diluted in the commercial kit dilution buffer before undergoing ELISA. Briefly, samples were incubated with Aβ detection antibody for 3 hours at RT then thoroughly washed. HRP-conjugated antibody was added to sample wells for 30 minutes. After another wash step, samples were incubated with stabilized chromogen for 30 minutes. The reaction was stopped using an acid-based stop solution and absorbance read at 450 nm using a PheraStar FS plate reader. Samples were run with a standard curve (4-parameter fit) to obtain a concentration readout. Final concentration is given as ng of Aβ per gram of tissue (Harwell and Coleman, 2016).

2.6. Immunohistochemistry and Gallyas staining

Mouse brains were fixed in 10% formalin for 24 hours before embedding in paraffin. Then, 7-μm-thick tissue sections were stained with the Gallyas silver staining method to identify neurofibrillary tangles as reported previously (Gilley et al., 2012; Kuninaka et al., 2015). They were examined with a Zeiss Axioplan microscope, and digital images were acquired using an AxioCam HRc camera.

The immunohistochemical labeling was performed using the ABC method. Sections were treated with 0.3% H2O2 to inhibit endogenous peroxidase and then blocked in 10% vol/vol normal horse serum in TBS (0.01 M Tris, 0.15 M NaCl, pH 7.4). After overnight incubation with diluted PHF-1 or AT8 antibodies (Inno-genetics), sections were incubated with biotin-conjugated horse anti-mouse antibodies followed by ABC complex (Vector Laboratories, Burlingame, CA, USA). Peroxidase activity was developed using diaminobenzidine as chromogen.

2.7. Statistical analysis

Statistical tests, as described in the figure legends, were performed using Prism software (GraphPad Software Inc, La Jolla, CA, USA). A p value of >0.05 was considered not significant (ns), and "p < 0.05, ""p < 0.01, and """"p < 0.001 was significant.

3. Results

3.1. Enhanced mitochondrial transport in 3-month-old MAPTβ301L/P301L knockin mouse peripheral nerves

First, we wanted to confirm whether the enhanced mitochondrial transport found previously in 8–11 months homozygous MAPTβ301L tau knockin mice (Gilley et al., 2012) was also present in younger, 3-month-old homozygous tau knockin mice, an age when TgCRND8 shows substantial axonal swellings and an increasing plaque density (Adalbert et al., 2009). To test this, we crossed MAPTβ301L knockin mice to Thy-1-mitoCFP-P (Mito-P) mice, which have CFP-labeled mitochondria in a subset of their neurons (Misgeld et al., 2007). The transport of CFP-labeled mitochondria was assessed in axons of explanted sciatic nerves from 3-month-old MAPTβ301L/P301L, MAPTβ301L/+ mice, and MAPTβ301L/+ mice. Peripheral nerves were used because we find quantitative analysis of axonal transport in nerves is more reproducible than that in CNS (Milde et al., 2015). We found that the number of CFP-labeled mitochondria moving in an anterograde direction was significantly higher in MAPTβ301L/P301L mice relative to wildtypes (Fig 1A). In MAPTβ301L/+ mice, there was a trend toward increased mitochondrial transport, but the difference was not statistically significant. No significant differences were found for retrograde transport (Fig 1B), and changes in anterograde flux were not accompanied by significant alterations to maximum speed or average speed (not shown). Thus, axons from young 3-month-old MAPTβ301L/P301L knockin mice show an increase in anterograde mitochondrial flux, similar to older (8–11 months) mice, prior to the reversal of this effect we have previously observed in old age (Gilley et al., 2012).

3.2. In the presence of the TgCRND8 mutation, MAPTβ301L/P301L reduces the axonal transport of mitochondria

Next, we assessed whether the presence of MAPTβ301L knockin mutation, alters the mitochondrial transport in TgCRND8 peripheral axons. Instead of the expected enhancement, we observed a significant decrease in anterograde mitochondrial flux in 3-month-old TgCRND8 mice homozygous for the MAPTβ301L knockin mutation (TgCRND8/MAPTβ301L/P301L) (Fig 1C), reminiscent of old-age MAPTβ301L/P301L mice without mutant APP (Gilley et al., 2012). Retrograde mitochondrial transport also declined, but this was not statistically significant in our sample (Fig 1D), and average speed of transport was unaltered (not shown). No significant differences in any transport parameters were identified for TgCRND8 mice heterozygous for the tau knockin mutation (TgCRND8/MAPTβ301L/+). These data indicate that in the presence of the TgCRND8 mutation, the effect of MAPTβ301L/P301L on axonal transport of mitochondria in young animals is reversed, suggesting an interaction between Aβ, or other APP processing products, and mutant tau that resembles the effect of normal aging.

3.3. Aβ1–42 is present in peripheral nerves of TgCRND8 mice and Aβ1–42 level in brain is not altered by MAPTβ301L/+ knockin mutation

Using ELISA, we quantified the Aβ1–42 in sciatic nerves from young (3 months) TgCRND8 mice and found that Aβ1–42 is present in peripheral nerves, at the age when the axonal transport measurements were conducted (Fig 2A). However, the levels were less than 10% of those in brain of the same animals (Fig 2B). This suggests that the use of peripheral nerves as a surrogate for CNS tissue in this study could underestimate the effect of Aβ, or other APP processing products, in combination with tau in the CNS. Brain levels of Aβ were not altered by the presence of the MAPTβ301L/+ knockin mutation (Fig 2B).

3.4. MAPTβ301L/P301L knockin mutation does not reduce the number of plaques and the associated axonal swellings in TgCRND8 brains

To test whether the presence of MAPTβ301L knockin mutation ameliorates amyloid-associated pathology, we quantified the number of amyloid plaques and the number of plaque-associated axonal swellings in the brains of TgCRND8/MAPTβ301L/P301L/YFP-H and TgCRND8/MAPTβ301L/YFP-H mice at 3 months of age. We found that the MAPTβ301L/P301L mutation did not significantly reduce the number of amyloid plaques (Fig 3A, C) or the associated axonal swellings in the brains of TgCRND8 mice (Fig 3B, D). Although as axonal transport was not enhanced in these animals as expected, it remains undetermined whether boosting transport can alleviate axonal swellings.

3.5. No morphologic alterations are present in TgCRND8/ MAPTβ301L/P301L spinal cord motor neurons and peripheral nerves

Histologic analysis of motor neurons from lumbar spinal cord segments L3-L5 and YFP positive axons from sciatic and tibial nerves
showed no obvious alterations in 3-month-old TgCRND8/MAPT P301L/P301L mice. Cresyl violet staining revealed motor neurons with normal morphology with centrally placed nuclei and a cytoplasm rich in rough endoplasmic reticulum (Fig 4A). Also, YFP positive axons from sciatic and tibial nerves were intact with no fragmentation or swellings along their length (Fig 4B, C). These observations show that the reduced anterograde axonal transport of mitochondria in peripheral nerves of TgCRND8/MAPT P301L/P301L mice occurs in morphologically normal axons and spinal cord motor neurons.

3.6. Absence of tau pathology

We previously showed that pathologic aggregation of hyper-phosphorylated tau does not occur in MAPT P301L/P301L tau knockin mice (Gilley et al., 2012). Similarly, in this study, no Gallyas-positive neurons or neuronal PHF-1 immunostaining for phosphorylated tau was detected in 6-month-old brains even after combining TgCRND8 transgene with MAPT P301L/P301L or MAPT P301L/+ knockin mutation (Fig 5). Only a puncta-like staining of dystrophic neurites around the Congo red positive plaques was found (Fig 5A). Hence, the presence of FAD-APP does not induce tau pathology in MAPT P301L tau knockin mice, at least up to the age of 6 months.

4. Discussion

In this study, we confirmed and extended our previous observation of increased anterograde mitochondrial transport in 8- to 11-month-old homozygous MAPT P301L knockin mice (Gilley et al., 2012) to 3-month-old homozygous knockin mice (Fig 1A) and to a trend in the same direction in heterozygotes. Retrograde transport (Fig 1B), maximum speed or average speed in either direction (not shown) were unaltered, and after crossing to TgCRND8, the numbers of plaque-associated axonal swellings or amyloid plaques in TgCRND8 brains were neither reduced nor increased by MAPT P301L/P301L.

By crossing the MAPT P301L knockin mice with an FAD model, TgCRND8 mice, our initial aim was to test whether boosting axonal transport can alleviate axonal swellings. We have selected TgCRND8 mice for our study as they develop robust axonal swellings at an early stage in amyloid pathology that we have extensively characterized, preceding axon and cell death, and major loss of synapses (Adalbert et al., 2009). Although these features arise in young animals, they closely resemble those in an aging human AD brain. Therefore, it is reasonable to use this model to test whether they can be alleviated by boosting axonal transport. These axonal swellings contain accumulations of fragmented mitochondria and other organelles, which suggest impairment of axonal transport.
Therefore, “unblocking” these swellings could alleviate AD-like histopathology and symptoms in TgCRND8 mice. Surprisingly, the presence of the homozygous MAPT*P301L* mutation significantly decreased the anterograde mitochondrial flux in 3-month-old TgCRND8 mice instead of enhancing it as we initially hypothesized, so it remains untested at present whether increasing axonal transport could alleviate plaques and/or axonal swellings.

Previous studies indicated that the physiological function of tau is required for aspects of FAD-APP pathogenesis. The block of axonal transport by Aβ_{1–42} oligomers in hippocampal primary cultures requires the presence of tau (Vosse, et al., 2010), and FAD-APP-induced behavioral deficits in mice are alleviated by removing tau (Roberson, et al., 2007). Recently, it was also reported that mutant tau with markedly reduced MT-binding capacity still enabled Aβ-induced axonal transport deficits (Vosse, et al., 2015). We now show that co-expression of MAPT*P301L* even at physiological levels, synergistically impairs axonal transport with FAD-APP. All these studies suggest that different tau isoforms, in the presence of Aβ, can lead to transport impairment.

Our findings support the hypothesis that Aβ and tau converge in axons to influence axonal transport or that tau itself is a downstream target of Aβ on the same pathway. Previously, it was suggested that tau may lie downstream of APP/Aβ or on a necessary pathway that converges onto a common, downstream target (Karran, et al., 2011; Morris, et al., 2011). In different neurodegenerative diseases, both in humans and in mice, plaques and tangles can arise independently of one another. In mice, neither FAD-APP nor FTDP-17T mutant tau causes both of these pathological hallmarks. Some human patients show amyloid without tau pathology, and FTDP-17T tau mutations cause tangles without plaques in frontotemporal dementia. These observations are consistent with convergent disease pathways, either of which can cause pathology when sufficiently activated. MAPT*P301L* knockin mutation does not enhance the generation of Aβ_{1–42} in the brains of 3-month-old TgCRND8 mice (Fig 2B), consistent with previous results using overexpression of tau in FAD-APP expressing cell lines or primary neuronal cultures (Goldsbury, et al., 2006). In addition, when tau deletion reduced cognitive deficits and excitotoxic damage in FAD-APP mice, there was no corresponding reduction in Aβ_{1–42} (Roberson, et al., 2007). This finding is important because if the synergistic effect of MAPT*P301L* knockin tau and FAD-APP were mediated by increasing Aβ_{1–42} processing, then that would favor a mechanism involving feedback on APP over a common downstream target for Aβ_{1–42} and MAPT*P301L* tau.

Tau pathology is not a feature of APP or PS1 mutant mice but has been seen when combined with overexpressing tau mutants. We were interested to see whether such pathology could be induced when mutant tau is expressed at physiological levels. The overexpression of Aβ did not induce pathologic aggregation of hyperphosphorylated tau in MAPT*P301L* tau knockin mice by the age of 6 months; however, we cannot rule out the possibility that tau pathology could develop at an older age. The puncta-like staining of phosphorylated tau in dystrophic neurites around amyloid plaques we observed in our study (Fig 5A,B) was reported previously in mutant APP and APP/PS1 transgenic mice, therefore is unlikely to reflect an action of MAPT mutation (Boutajangout, et al., 2004; Kurt, et al., 2003; Tomidokoro, et al., 2001).

It is worth noting that alternative models that overexpress both mutant APP and MAPT*P301L* show late development of tau tangles; a double transgenic requiring 9 months and a different 3×Tg model not showing pathology until 12 months of age (Lewis, et al., 2001; Oddo, et al., 2003). It may be due to the knockin nature of the MAPT*P301L* in our model that neurofibrillary pathology cannot develop during the normal life span of our mice.

Some evidence suggests that increased tau expression and/or altered tau isoform ratio are more important for the development of neurofibrillary pathology in a mouse than is the presence of an FTDP-17T mutation (Adams, et al., 2009; Gotz, et al., 2001). The presence of tau at physiological levels and with the expected isoform ratios in our MAPT*P301L* tau knockin mice could be responsible for the absence of tau pathology. In addition, it could be that murine tau has less propensity for aggregation in vivo compared to human tau (Allen, et al., 2002; Ando, et al., 2011; Sahara, et al., 2002).
The decline in axonal transport seen when combining the APP and MAPT<sup>P301L</sup> mutations may anticipate the age-related effect of MAPT<sup>P301L</sup> tau mutation alone. As Aβ levels increase with age even without APP mutation (Lesne et al., 2013), our double mutants may have modeled this process in younger animals. Thus, we suggest that this Aβ rise could contribute to age-related decline in fronto-temporal dementia. It would be important to repeat our observations with other mutant tau knockin mice (e.g., R406W) as well, to know whether axonal transport impairment in the presence of Aβ is a consistent effect of FTDP tau mutations. In addition, it would be interesting to test whether amyloid-independent pathogenic mechanism can also lead to axonal transport impairment observed in our model, by crossing the MAPT<sup>P301L</sup> tau knockin mice with wild-type human APP overexpressing mice (Mucke et al., 2000).

In these mice, the human wild-type APP processing is basically non-amyloidogenic (Simon et al., 2009).

Using our mouse model, we found that Aβ<sub>1-42</sub> is present in peripheral nerves at the age when the axonal transport measurements were done (Fig. 2A), similar to previous studies in the peripheral nerves of other APP mutant mice (Jollivalt et al., 2012). In our model, the Aβ<sub>1-42</sub> levels in the peripheral nerves were less than 10% of those in the brains of the same animals, which suggest that the effect of Aβ in combination with tau in the CNS could be much stronger.

In the presence of the APP mutation, MAPT<sup>P301L/P301L</sup> knockin failed to enhance axonal transport of mitochondria; therefore, new strategies have to be used to increase transport (Hinckelmann et al., 2013). Drugs increasing MT acetylation may be useful to boost axonal transport in AD. Tubulin acetylation is reduced in the brains of patients with AD (Hinckelmann et al., 2013) and in the brains of various mouse models of AD (Govindarajan et al., 2013; Kim et al., 2012). Studies so far showed that HDAC6 inhibitors reverse the amyloid beta-induced changes in α-tubulin acetylation and mitochondrial trafficking in cultured hippocampal neurons (Kim et al., 2012) and HDAC6 knockout in a mouse model of AD restores α-tubulin acetylation in the brain and cognitive function in AD mice (Govindarajan et al., 2013). Another approach to improve axonal transport could be to inhibit cJun N-terminal kinase (JNK) activity. JNK hyperactivity has been reported in models of AD, and the inhibition of JNK activity in vivo was shown to be neuroprotective in animal models (Mehan et al., 2011). JNK3 inhibition rescued axonal transport defects induced by pathogenic fragments of huntingtin in a squid model of axonal transport (Morfini et al., 2009).

In summary, we confirmed and extended our previous observation of an increase in mitochondrial transport in young MAPT<sup>P301L</sup> knockin homozygous mice to animals aged 3 months and observed a nonsignificant trend also in heterozygotes. This could represent early consequences of the tau dysfunction that may be relevant to FTDP-17 pathogenesis in humans as they age. Our results demonstrate that Tg<i>CRND8</i> and MAPT<sup>P301L/P301L</sup> mutations in combination reduce the axonal transport of mitochondria in peripheral nerves, in contrast to the enhancement of transport in young MAPT<sup>P301L/P301L</sup> mice. This exciting finding suggests that Aβ and tau converge in axons to inactivate axonal transport or that tau itself is a downstream target of amyloid beta on the same pathway. MAPT<sup>P301L</sup> mutation did not significantly reduce the number of plaque associated axonal swellings or the number of amyloid plaques in Tg<i>CRND8</i> brains and did not alter Aβ levels in brain. Our FAD-APP and MAPT<sup>P301L</sup> tau knockin mouse model may be useful to study how amyloid beta peptide and tau combine in pathogenesis.

Disclosure statement

The authors have no actual or potential conflicts of interest.

References

Adalbert, R., Coleman, M.P., 2013. Review: axon patholgy in age-related neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 39, 90–108.
Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S.A., Kerschensteiner, M., Misgeld, T., Coleman, M.P., 2009. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 132 (Pt 2), 402–416.
Adalbert, R., Nogradi, A., Szabo, A., Coleman, M.P., 2006. The slow Wallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy. Eur. J. Neurosci. 24, 2163–2168.
Adams, S.J., Crook, R.J., Deture, M., Randle, S.J., Innes, A.E., Yu, X.Z., Lin, W.L., Dugger, B.N., McBride, M., Hutton, M., Dickson, D.W., McGowan, E., 2009. Overexpression of wild-type murine tau results in progressive taoopathy and neurodegeneration. Am. J. Pathol. 175, 1598–1609.
Allen, B., Ingram, E., Takao, M., Smith, M.J., Jakes, R., Virdie, K., Yoshida, H., Holzer, M., Craxton, M., Emerson, P.C., Attori, C., Miglioli, A., Crowther, R.A., Ghetti, B., Spellantian, M.C., Goedert, M., 2002. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340–9351.
Ando, K., Leroy, K., Herala, C., Yilmaz, Z., Auteleath, M., Suin, V., De Decker, R., Brion, J.P., 2011. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am. J. Pathol. 178, 803–816.
Andrews, S., Gilley, J., Coleman, M.P., 2010. Difference tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parameters. J. Neurosci. Methods 193, 281–287.
Beirouss, B., Berek, L., Adalbert, R., Wagner, D., Grunme, D.S., Addicks, K., Ribchester, R.R., Coleman, M.P., 2004. Quantitative and qualitative analysis of Wallerian degeneration: restricted axonal labelling in YFP-mice. J. Neurosci. Methods 134, 23–35.
Bellucci, A., Rossi, M.C., Grossi, C., Fiorentini, A., Lucarrini, I., Casamenni, F., 2007. Abnormal processing of tau in the brain of aged Tg<i>CRND8</i> mice. Neurobiol. Dis. 27, 322–338.
Bertrand, A., Khan, U., Hoang, D.M., Novikov, D.S., Krishnamurthy, P., Rajamohamed Sait, H.B., Little, B.W., Sigurdsson, E.M., Wadghiri, Y.Z., 2013. Non-invasive, in vivo monitoring of neuronal transport impairment in a model of tauopathy using MEMRI. NMR in Bioimage-36, 543–7006.
Boutajangout, A., Auteleath, M., Blanchard, V., Toucchet, N., Tremp, G., Pradier, L., Brion, J.P., 2004. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer’s disease mutants of APP and presenilin-1. Neurobiol. Dis. 15, 47–60.
Boyette-Davis, J.A., Cata, J.P., Driver, L.C., Novy, D.M., Bruel, B.M., Mooreing, D.L., Wendelschafer-Crab, G., Kennedy, W.R., Dougherty, P.M., 2013. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother. Pharmacol. 71, 619–626.
Brunden, K.R., Ballatore, C., Lee, V.M., Smith 3rd, A.B., Trojanowski, J.Q., 2012. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem. Soc. Trans. 40, 661–668.
Chishiti, M.A., Yang, D.S., Janus, C., Phinney, A.L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., Turner, S., Lozza, G., Grilli, M., Kunicki, S., Morissette, C., Paquette, J., Gervais, F., Bergeron, C., Fraix, P.E., Carlson, G.A., George-Hyslop, E.S., Westaway, D., 2001. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562–21567.
De Vos, K.J., Grionesor, A.J., Ackerley, S., Miller, C.C., 2008. Role of axonal transport in neurodegenerative disease. Dali Rev. Neurosci. 31, 151–173.
Feng, C., Mellor, R.H., Bernstein, M., Keller-Peck, C., Nguyen, Q.T., Wallace, M., Nervonde, J.M., Lichtman, J.W., Sanes, J.R., 2000. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28, 41–51.
Gilley, J., Seereeram, A., Ando, K., Mosley, S., Andrews, S., Kerschensteiner, M., Misgeld, T., Brion, J.P., Anderton, B., Hanger, D.P., Coleman, M.P., 2012. Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a Tg<sup>P301L</sup> tau knockin mouse. Neurobiol. Aging 33, 621.e1–621.e15.

Acknowledgements

The authors would like to thank Simon Walker for imaging advice and Anne Segonds-Pichon for assistance with statistical analysis.

This work was supported by Alzheimer’s Research UK (ART/ PG2009/2 to RA), MRC project grant (MR/L003813/1 to RA and SG), Medical Research Council studentship (SM), Alzheimer’s Research UK studentship (ARUKPhD2013-13 to CD), Biotechnology and Biological Sciences Research Council Institute Strategic Programme Grant (MPC), the Foundation for Alzheimer Research (FRA/SAO) (JPB) and the Belgian F.N.R.S. (KA and JPB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Goldbursky, C., Mocanu, M.M., Thies, E., Kather, C., Haass, C., Keller, P., Birnart, J., Mandelkow, E., Mandelkow, E.M., 2006. Inhibition of APP trafficking by tau protein does not increase generation of amyloid-beta peptides. Traffic 7, 873–888.

Gott, J., Chen, F., van Dophe, J., Nitsch, R.M., 2001. Formation of neurofilibrillary tangles in P301t tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1031–1034.

Govindarajan, N., Rao, P., Burkhard, S., Sananbenesi, F., Schlenzke, O., Bruch, F., Zhang, B., Nakagawa, Y., Lee, M.K., Trojanowsky, J.Q., Lee, V.M., 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751–762.

Ittner, L.F., Tse, K., Kohn, Y.D., Jung, E.S., Lee, W., Oh, S., Jeon, N.L., Moon, J.H., 2012. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 7, e42983.

Kim, C., Choi, H., Jung, E.S., Lee, W., Oh, S., Jeon, N.L., Moon, J.H., 2012. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 7, e42983.

Kunikata, N., Kawaguchi, M., Ogawa, M., Sato, A., Arima, K., Murayama, S., Saito, Y., 2015. Simplification of the modified gallyas method. Neuropathology 35, 10–15.

Kurt, M.A., Davies, D.C., Kidd, M., Duff, K., Howlett, D.R., 2003. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurol Sci 24, 463–467.

Lazarov, O., Morahan, S., Meena, H., Sharma, D., Sankhla, R., 2011. JNK: a stress-activated protein kinase. In: Biochemistry and Molecular Biology of Mammalian Cells (pp. 271–291). Academic Press.

Lin, W.L., Yen, S.H., Dickson, D.W., Davies, P., Hutton, M., 2000. Neurofilament hyperphosphorylation in hippocampal neurons by different mechanisms. J. Neurosci. 20, 8967–8977.

Majid, T., Ali, Y.O., Venkitaramani, D.V., Jang, M.K., Lu, H.C., Pautler, R.G., 2014. In vivo transport blockage of neurodegenerative anomalies. J. Mol. Neurosci. 43, 376–390.

Masters, C.L., Bateman, R., Blennow, K., Rowe, C.C., Sperling, R.A., Cummings, J.L., 2003. Enhanced neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402–405.

Metherate, R., Mattson, M.P., Akbari, Y., LaFerla, F.M., 2003. Triple-transgenic mouse model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409–421.

Mucke, L., Masliah, E., Yu, Q.G., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., 2006. Tau blocks axonal transport in neurodegenerative disorders. Trends Cell Biol. 23, 634–643.

Nakamura, N., Lewis, J., DeTure, M., McGowan, E., Dickson, D.W., Hutton, M., Yen, S.H., 2002. Assembly of tau in transgenic animals expressing P301t tau: alteration of tau phosphorylation and solubility. J. Neurochem. 83, 1498–1508.

Oroz, C., Banchi, M., Malvindi, A., Defossez, P.A., De Camilli, P., 2010. Microtubule-stabilizing drugs alter fast axonal transport by targeting tau in vivo. J. Neurosci. 30, 15088–15097.

Powers, M.L., de la Monte, S., 2015. Alzheimer’s disease: an appraisal for the development of therapeutics. Nat. Rev. Dis. Primers 1, 15056.

Powers, M.L., de la Monte, S., 2015. Alzheimer’s disease: an appraisal for the development of therapeutics. Nat. Rev. Dis. Primers 1, 15056.